roches

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the…

3 weeks ago

FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase…

5 months ago

Roches Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

July 22, 2025 12:45 ET  | Source: F. Hoffmann-La Roche Ltd Participation certificates (Partizipationsscheine) with a nominal value of CHF…

7 months ago